Proactive Investors - Run By Investors For Investors

EMIS has fallen too far, says house broker Numis Securities

CEO Andy Thorburn is focused for now on improving underlying operating procedures and performance, including a focus on the replacement GP systems contract for England, now perhaps 15-18 months away
Doctor's surgery
The service issues with NHS Digital resulted in a provision of £11mln in the 2017 results

Numis Securities has turned bullish on EMIS Group PLC (LON:EMIS) now the healthcare software firm's shares have fallen a fifth this year.

The software firm's nominated adviser admitted that today's full-year results were largely as trailed in January's trading statement, although as a consequence of slightly higher-than-expected guidance on costs Numis has trimmed its 2018 earnings per share forecasts by 2%.

READ: EMIS Group shares tumble 15% as it is hit by contract delays

The shares are now “too cheap”, although Numis concedes there is still much to do to reinvigorate growth.

The house broker's recommendation has moved to 'buy' from 'hold', although the price target has been slashed to 880p from 1,000p, reflecting the dismal share price performance in 2018.

The shares currently trade at 792p, up 10% on the day.

“The three key areas of focus for management for now are:

  1. Preparation for the key England GP's system replacement contract, which now looks likely during 2019 (we look for buyer focus to be on enabling new models of care, reducing overall NHS cost and improving service, rather than price, but perceived risk will remain);
  2. An upgrade to the group's core EMIS Web clinical management system, modernising it and making it more flexible;
  3. Resolution of the service level issues, working collaboratively with the customer,” Numis stated.

In the background management is working on detailed plans for growth, EMIS's Nomad revealed.

“While we see some risk of investor impatience for growth plans, we think that Andy Thorburn's approach is entirely appropriate and will help to build investor confidence in due course,” it concluded.

View full EMIS profile View Profile

EMIS Group Timeline

Related Articles

Nemaura Medical Inc CEO Dr Faz Chowdhury
November 05 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018
myLotus testing kit
October 31 2018
The launch at the Fertility Show in London at the start of November is the first step in a switch in focus brought about by new executive chairman Matthew Walls
November 14 2018
The goal of the program is to extend the visualization extracted from 2D ultrasound images and visualize 4D images

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use